GMGautam Maddineni

Gautam Maddineni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gautam Maddineni has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of curcumin on anthropometric measurements in nonalcoholic fatty liver disease: An umbrella meta-analysis study

    by Abinash Mahapatro, Herby Jeanty, Saisree Reddy Adla Jala, Kavya Priya Somu, Gautam Madineni, Elan Mohanty, Mohammed Dheyaa Marsool, Pourya Shamsi, Maryam Shahriari Namin, Shahin Abbaszadeh, et al.

    Background: Metabolic-associated fatty liver disease (MAFLD) affects approximately 30% of the global population and is associated with obesity and metabolic syndrome. Anthropometric indices such as body mass index (BMI), waist circumference (WC), and weight are crucial markers for evaluating the progression of MAFLD. Curcumin, a bioactive compound with anti-inflammatory and antioxidant properties, has been investigated for its potential to improve metabolic outcomes. This umbrella review aimed to systematically evaluate the effects of curcumin supplementation on anthropometric indices in patients with MAFLD, considering epidemiological strength and power analysis. Methods: An umbrella review of meta-analyses from randomized controlled trials was conducted. PubMed, Scopus, and Web of Science were searched up to September 2024. Meta-analyses assessing curcumin’s effects on BMI, weight, and WC in MAFLD patients were included. Quality was assessed using the A Measurement Tool to Assess Systematic Reviews version (AMSTAR-2) tool, and heterogeneity was evaluated using the I 2 statistic. Statistical analyses were performed using R and Stata 18 software. Results: Curcumin supplementation had no significant effect on BMI (standardized mean difference [SMD]: −0.01; 95% confidence interval [CI]: −0.24 to 0.21, P = .91) with low power (1-β = 0.03) and a low epidemiological grade according to GRADE criteria. Similarly, curcumin showed no significant effect on WC (SMD: −0.27; 95% CI: −0.57 to 0.04, P = .08) with high power (1-β = 0.96) but low epidemiological strength. However, curcumin significantly reduced weight (SMD: −0.12; 95% CI: −0.19 to −0.04, P < .01) with moderate power (1-β = 0.56) and moderate epidemiological strength. No significant effect of dose or effect of supplementation duration was found. Conclusion: Curcumin supplementation may result in a statistically detectable but clinically modest reduction in body weight in patients with MAFLD, while showing limited or no efficacy on BMI and waist circumference. The epidemiological strength of the evidence varies across outcomes and is of low to moderate quality. Further well-designed, high-quality randomized controlled trials are needed to confirm the clinical relevance of curcumin’s effects on anthropometric indices.

  • Open Access

    The impact of gut microbiome modulation on anthropometric indices in metabolic syndrome: an umbrella review

    by Maryam Sadat Aleali, Abinash Mahapatro, Gautam Maddineni, Ruchir Paladiya, Herby Jeanty, Elan Mohanty, Mohit Mirchandani, Ali Jahanshahi, Pavan Devulapally, Azin Alizadehasl, et al.

    Background: Metabolic syndrome (MetS) is a complex disorder characterized by a cluster of metabolic risk factors. Recent research highlights the gut microbiome’s role in metabolic regulation, suggesting that modulation through probiotics, prebiotics, and synbiotics may provide a novel approach to managing MetS. This umbrella review aims to integrate insights from existing meta-analyses to explore how changes in gut microbiota influence key body measurement indicators in individuals with MetS. Methods: A systematic search of PubMed, Scopus, and Web of Science databases identified meta-analyses that assessed the impact of probiotics, prebiotics, or synbiotics on anthropometric indices in MetS patients. Results: The results indicated that microbial therapy leads to a significant reduction in body mass index (BMI) (SMD: −0.22; 95% CI: −0.35 to −0.09; P < 0.01) and waist circumference (WC) (SMD: −0.47; 95% CI: −0.80 to −0.15; P < 0.01). However, microbial therapy did not significantly affect body fat mass (SMD: −0.30; 95% CI: −0.64 to 0.02; P = 0.06), body fat percentage (SMD: −0.29; 95% CI: −0.62 to 0.03; P = 0.07), waist-to-hip ratio (SMD: −0.09; 95% CI: −0.46 to 0.28; P = 0.63), and weight (SMD: −0.06; 95% CI: −0.21 to 0.08; P = 0.37). Conclusions: Gut microbial modulation, mainly through probiotics and synbiotics, shows promise in reducing BMI and WC in MetS patients. However, its effects on other anthropometric indices remain uncertain, warranting further high-quality research to fully understand microbial interventions’ therapeutic potential.


  • Open Access

    The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment

    by Gautam Maddineni, Sri J. Obulareddy, Ruchir Damjibhai Paladiya, Rohan Reddy Korsapati, Shika M. Jain, Herby Jeanty, Fnu Vikash, Nayanika Chowdary Tummala, Samatha P. Shetty, Arezoo Ghazalgoo, et al.

    Background and aim: Currently, there are no authorized medications specifically for non-alcoholic fatty liver disease (NAFLD) treatment. Studies indicate that changes in gut microbiota can disturb intestinal balance and impair the immune system and metabolism, thereby elevating the risk of developing and exacerbating NAFLD. Despite some debate, the potential benefits of microbial therapies in managing NAFLD have been shown. Methods: A systematic search was undertaken to identify meta-analyses of randomized controlled trials that explored the effects of microbial therapy on the NAFLD population. The goal was to synthesize the existing evidence-based knowledge in this field. Results: The results revealed that probiotics played a significant role in various aspects, including a reduction in liver stiffness (MD: −0.38, 95% CI: [−0.49, −0.26]), hepatic steatosis (OR: 4.87, 95% CI: [1.85, 12.79]), decrease in body mass index (MD: −1.46, 95% CI: [−2.43, −0.48]), diminished waist circumference (MD: −1.81, 95% CI: [−3.18, −0.43]), lowered alanine aminotransferase levels (MD: −13.40, 95% CI: [−17.02, −9.77]), decreased aspartate aminotransferase levels (MD: −13.54, 95% CI: [−17.85, −9.22]), lowered total cholesterol levels (MD: −15.38, 95% CI: [−26.49, −4.26]), decreased fasting plasma glucose levels (MD: −4.98, 95% CI: [−9.94, −0.01]), reduced fasting insulin (MD: −1.32, 95% CI: [−2.42, −0.21]), and a decline in homeostatic model assessment of insulin resistance (MD: −0.42, 95% CI: [−0.72, −0.11]) (P<0.05). Conclusion: Overall, the results demonstrated that gut microbiota interventions could ameliorate a wide range of indicators including glycemic profile, dyslipidemia, anthropometric indices, and liver injury, allowing them to be considered a promising treatment strategy.


  • Open Access

    Can modulation of gut microbiota affect anthropometric indices in patients with non-alcoholic fatty liver disease? An umbrella meta-analysis of randomized controlled trials

    by Ehsan Amini-Salehi, Sandeep Samethadka Nayak, Gautam Maddineni, Abinash Mahapatro, Mohammad-Hossein Keivanlou, Saman Soltani Moghadam, Azin Vakilpour, Maryam Sadat Aleali, Farahnaz Joukar, Mohammad Hashemi, et al.

    Background and aim: Modulating the gut microbiota population by administration of probiotics, prebiotics, and synbiotics has shown to have a variety of health benefits in different populations, particularly those with metabolic disorders. Although the promising effects of these compounds have been observed in the management of patients with non-alcoholic fatty liver disease (NAFLD), the exact effects and the mechanisms of action are yet to be understood. In the present study, we aimed to evaluate how gut microbiota modulation affects anthropometric indices of NAFLD patients to achieve a comprehensive summary of current evidence-based knowledge. Methods: Two researchers independently searched international databases, including PubMed, Scopus, and Web of Science, from inception to June 2023. Meta-analysis studies that evaluated the effects of probiotics, prebiotics, and synbiotics on patients with NAFLD were entered into our umbrella review. The data regarding anthropometric indices, including body mass index, weight, waist circumference (WC), and waist-to-hip ratio (WHR), were extracted by the investigators. The authors used random effect model for conducting the meta-analysis. Subgroup analysis and sensitivity analysis were also performed. Results: A total number of 13 studies were finally included in our study. Based on the final results, BMI was significantly decreased in NAFLD patients by modulation of gut microbiota [effect size (ES): −0.18, 05% CI: −0.25, −0.11, PP=0.055, and ES: −0.24, 05% CI: −0.75, 0.26, P=0.353, respectively). The results of subgroup analysis showed probiotics had the most substantial effect on decreasing BMI (ES: −0.77, 95% CI: −1.16, −0.38, PPP=0.001). Conclusion: In conclusion, the present umbrella meta-analysis showed that although modulation of gut microbiota by administration of probiotics, prebiotics, and synbiotics had promising effects on BMI, no significant change was observed in the WC and weight of the patients. No sufficient data were available for other anthropometric indices including waist-to-hip ratio and waist-to-height ratio and future meta-analyses should be done in this regard.